Target type: biologicalprocess
Any process that activates or increases the frequency, rate or extent of cysteine-type endopeptidase activity involved in apoptotic signaling pathway. [GOC:mtg_apoptosis]
Positive regulation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway is a complex biological process that plays a crucial role in programmed cell death. It involves the activation of specific cysteine-type endopeptidases, also known as caspases, which are critical mediators of apoptosis. The process can be initiated by various intracellular and extracellular stimuli, including DNA damage, growth factor deprivation, and cytotoxic agents.
Here is a detailed description of the key steps involved in the positive regulation of cysteine-type endopeptidase activity in apoptotic signaling:
1. **Initiator caspase activation:**
- **Intrinsic pathway (mitochondrial pathway):** In response to stress signals, mitochondria release cytochrome c into the cytoplasm, which binds to apoptotic protease activating factor 1 (Apaf-1). This complex activates caspase-9, an initiator caspase.
- **Extrinsic pathway (death receptor pathway):** Binding of death ligands (e.g., TNF-α, Fas ligand) to their corresponding death receptors (e.g., TNFR1, Fas) triggers the assembly of the death-inducing signaling complex (DISC). This complex recruits and activates caspase-8, another initiator caspase.
2. **Executioner caspase activation:** Initiator caspases (caspase-9 or caspase-8) activate executioner caspases (caspase-3, caspase-6, and caspase-7) through proteolytic cleavage. These executioner caspases are responsible for dismantling the cell by targeting various cellular components.
3. **Cleavage of cellular substrates:** Executioner caspases cleave specific cellular substrates, leading to:
- **DNA fragmentation:** Caspase-activated DNase (CAD) is activated by caspase-3, leading to DNA cleavage and nuclear fragmentation.
- **Cytoskeletal disruption:** Caspases cleave proteins involved in cytoskeletal organization, causing cell shape changes and membrane blebbing.
- **Apoptosis-inducing factor (AIF) release:** AIF is a mitochondrial protein that can activate caspase-independent apoptotic pathways.
4. **Formation of apoptotic bodies:** The apoptotic cell fragments into membrane-bound apoptotic bodies, which are engulfed by phagocytic cells, preventing inflammation.
**Key regulatory proteins:**
- **Bcl-2 family proteins:** This family of proteins regulates the release of cytochrome c from mitochondria. Anti-apoptotic proteins (e.g., Bcl-2, Bcl-xL) inhibit apoptosis, while pro-apoptotic proteins (e.g., Bax, Bak) promote apoptosis.
- **Inhibitors of apoptosis proteins (IAPs):** These proteins bind to and inhibit caspases, preventing their activation.
- **Caspase-activating enzymes (CASPases):** These are the main players in the apoptotic signaling pathway, responsible for cleaving specific cellular substrates.
**Conclusion:**
Positive regulation of cysteine-type endopeptidase activity involved in apoptotic signaling is a tightly regulated process that ensures proper elimination of damaged or unwanted cells. Disruptions in this pathway can lead to various diseases, including cancer and autoimmune disorders.'
"
Protein | Definition | Taxonomy |
---|---|---|
Galectin-9 | A galectin-9 that is encoded in the genome of human. [PRO:DNx, UniProtKB:O00182] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
lactose | beta-lactose : The beta-anomer of lactose. lactose : A glycosylglucose disaccharide, found most notably in milk, that consists of D-galactose and D-glucose fragments bonded through a beta-1->4 glycosidic linkage. The glucose fragment can be in either the alpha- or beta-pyranose form, whereas the galactose fragment can only have the beta-pyranose form. Lactose: A disaccharide of GLUCOSE and GALACTOSE in human and cow milk. It is used in pharmacy for tablets, in medicine as a nutrient, and in industry. | lactose | |
methyl alpha-d-galactopyranoside | methyl alpha-D-galactoside : An alpha-D-galactoside having a methyl substituent at the anomeric position. methyl-galactopyranoside: structure in first source | alpha-D-galactoside; methyl D-galactoside; monosaccharide derivative | |
methyl beta-galactoside | methyl beta-D-galactoside : A beta-D-galactopyranoside having a methyl substituent at the anomeric position. methyl beta-galactoside: RN given refers to (beta-D)-isomer methyl galactoside : A methyl glycoside in which the H of the OH group on C-1 of galactose is replaced by a methyl group. | beta-D-galactoside; methyl D-galactoside; monosaccharide derivative | |
thiodigalactoside | thiodigalactoside: RN given refers to beta-D-galactopyranoside (D-Gal)-isomer | ||
methyl lactoside | beta-D-Gal-(1->4)-beta-D-Glc-OMe : A methyl glycoside comprising methyl beta-D-glucoside having an beta-D-galactosyl residue at the 4-position. | disaccharide derivative; methyl glycoside | |
n-acetyllactosamine | N-acetyllactosamine : A beta-D-galactopyranosyl-(1->4)-N-acetyl-D-glucosamine having beta-configuration at the reducing end anomeric centre. N-acetyllactosamine: RN given refers to D-isomer | beta-D-Galp-(1->4)-D-GlcpNAc | |
galactal | galactal: RN given refers to cpd with unspecified isomeric designation; structure | anhydrohexose; glycal |